Monitor for any future conversion to a 13D filing, which would signal activist intent. The stake is passive for now, but the presence of multiple healthcare-focused funds (Frazier Life Sciences at 5.9%, Bank of America at 7.4%) suggests institutional interest in Q32 Bio's pipeline ahead of Phase 3 data.
QTTB drugs
QTTB drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $9.34entry
- T+1 · 7d ago −0.11%α +0.26% · $9.33
- T+5 · 20h ago −11.24%α −9.55% · $8.29
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Boxer Capital Management and related entities filed an amended Schedule 13G disclosing a 7.9% passive stake (2,357,922 shares) in Q32 Bio as of September 30, 2026. This is a new position above the 5% threshold, indicating a meaningful but non-activist investment by a healthcare-focused fund. The filing is routine and does not signal activist intent.
Key Financial Metrics
Key Facts
- Boxer Capital Management and related entities hold 2,357,922 shares of Q32 Bio common stock
- Stake represents 7.9% of shares outstanding based on 29,769,466 shares as of August 3, 2026
- Filing is an amendment to Schedule 13G, indicating passive investment intent
- Boxer Capital is a Delaware LLC with business address in San Diego, CA
- Aaron Davis is the manager of Boxer Capital and a reporting person
Financial Impact
Stake valued at approximately $21M based on $267M market cap and 7.9% ownership
Risk Factors
- Boxer Capital could convert to activist (13D) filing in the future
- Concentration of institutional ownership may increase stock volatility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001213900-26-116951 |
| Document: 0001213900-26-116951-index.html | 0001213900-26-116951 |
| Document: 0001213900-26-116951.txt | 0001213900-26-116951 |
Track record
23 reports on QTTB
3 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +48.47% at T+60 after the Jul 14, 2026 report. 6 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $8.29 Now $8.29 −0.00% settles Dec 16
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $8.47 Now $8.29 −2.13% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $8.71 Now $8.29 −4.82% settles Dec 15
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Viewing Entry $9.34 Now $8.29 −11.24% settles Dec 8
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $9.34 Now $8.29 −11.24% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $8.97 Now $8.29 −7.58% settles Dec 3
- Oct 28, 202619d ago SC 13G Neutral 4/10 Entry $9.06 Now $8.29 −8.50% settles Nov 25
- Oct 9, 20265w ago SC 13G Neutral 4/10 Entry $8.74 to $9.36 Now $8.29 −5.15% ▲ +7.09% +10.36% vs SPY
- Sep 30, 20266w ago 8-K Bullish 6/10 Entry $8.27 to $8.71 Now $8.29 +0.24% ▲ +5.32% +4.05% vs SPY
- Sep 14, 20269w ago 8-K Neutral 3/10 Entry $10.91 to $8.74 Now $8.29 −24.01% ▼ −19.89% −22.15% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers